A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

The Food and Drug Administration should look for ways to streamline regulations on new U.S. drug manufacturing facilities to ...

The company added to a recent flurry of pledges by pharmaceutical companies, promising $11 billion in new capital and ...

CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...

A vocal opponent of his predecessor Peter Marks, Vinay Prasad will now lead the office tasked with reviewing some genetic ...

Experts say market turmoil has made it harder for buyers and sellers to agree on price, which can be an especially imposing ...

Siren Biotechnology is trying to raise $5 million via the type of crowdfunding round that’s rarely used by young drugmakers.

Vor Bio, Korro Bio, Insitro and Rallybio revealed plans to lay off chunks of their respective workforces in the latest job ...

While updated study results confirmed the drug lowers a target protein, the therapy's effect on clinical outcomes was less ...

The cuts to three advanced drug programs were “inevitable” given the company’s “unsustainable cash burn,” one analyst wrote ...

Sales of the company’s copycat to J&J’s blockbuster reached $150 million in the first quarter, adding to a surge in revenue ...

The advisory committee meeting is an important step in the process of readying boosters for the fall and winter season, but ...